title: [Biologic therapy with anti-TNFα in spondyloarthritides and other autoimmune diseases].
abstract: OBJECTIVE
  To evaluate the efficacy of the anti-TNFα (Tumor Necrosis Factor alpha) drugs in a variety of pathologic conditions such as psoriatic arthritis, undifferentiated entheso-arthritides, chronic inflammatory bowel diseases, adult onset Still's disease, Behcet disease.
  
  
  METHODS
  Review of all published studies evaluating the efficacy of these drugs (mainly infliximab and etanercept, adalimumab to a lesser degree) on the above diseases.
  
  
  RESULTS
  Results are reported for each pathologic condition. Both drugs showed to be very efficacious in all the above conditions, except Crohn disease where etanercept does not seem adequate.
  
  
  CONCLUSIONS
  Both drugs work extremely well, even though comparison between infliximab and etanercept efficacy cannot be performed, due to the lack of a direct comparison.
authors.affiliation: DIMIMP, Sezione di Reumatologia, Università degli Studi di Bari, Italia. g.lapadula@reumbari.uniba.it
authors.forename: G
authors.initials: G
authors.lastname: Lapadula
mesh_terms: D000068879:Adalimumab; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D001327:Autoimmune Diseases / Q000188:drug therapy*; D001528:Behcet Syndrome / Q000188:drug therapy; D001691:Biological Therapy; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003424:Crohn Disease / Q000188:drug therapy; D004311:Double-Blind Method; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000069285:Infliximab; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000037:antagonists & inhibitors; D025241:Spondylarthritis / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept